/study / lectures / Special Populations XI

Anesthesia for Immunocompromised and Oncology Patients

TEXT

Special Populations XI · 9 min read

Cancer and immunosuppression rewrite cardiopulmonary reserve, coagulation, and infection risk. The pre-op assessment is doing most of the work.

After this lesson you can

2 min read5 sections

Categories of immunocompromise

PRIMARY (congenital) immunodeficiencies — SCID, CVID, CGD; rare, present in pediatric anesthesia.

HEMATOLOGIC malignancies — leukemias, lymphomas, multiple myeloma; treatment-related immunosuppression dominates.

SOLID-ORGAN TRANSPLANT recipients on chronic immunosuppression — tacrolimus, mycophenolate, prednisone; risk of opportunistic infection (CMV, PJP, aspergillus), nephrotoxicity, drug interactions with anesthetics.

CHEMOTHERAPY/RADIATION-induced — bone marrow suppression timed predictably (nadir 7–14 days post-cycle), mucositis, neutropenia.

HIV/AIDS — well-controlled HIV (CD4 >500, undetectable viral load) is now ASA 2 for routine surgery; antiretroviral interactions matter.

Long-term steroid use — adrenal suppression, hyperglycemia, infection risk.

Cancer-treatment cardiotoxicity

ANTHRACYCLINES (doxorubicin, daunorubicin) — DOSE-DEPENDENT dilated cardiomyopathy

cumulative dose >450–550 mg/m² markedly increases risk

check echo for EF before elective surgery if exposure >300 mg/m²

TRASTUZUMAB (Herceptin, HER2 inhibitor) — REVERSIBLE cardiomyopathy

~10% incidence symptomatic HF

check EF before surgery if recent exposure

RADIATION (especially thoracic for breast, lymphoma) — accelerated CAD, valvular fibrosis, pericardial constriction

effects emerge years to decades after exposure

mediastinal radiation = high-risk preop coronary evaluation

TYROSINE KINASE INHIBITORS (sunitinib, imatinib) — QT prolongation, HF, hypertension.

IMMUNE CHECKPOINT INHIBITORS (nivolumab, pembrolizumab) — autoimmune myocarditis (rare, fatal), pneumonitis, hepatitis, colitis, endocrinopathies.

Hematologic + pulmonary effects

BONE MARROW SUPPRESSIONneutropenia <500 raises infection risk markedly; consider G-CSF, neutropenic precautions, delay elective surgery until count recovers.

THROMBOCYTOPENIA <50,000 contraindicates neuraxial; <20,000 raises spontaneous bleeding risk.

ANEMIAchronic, often optimized preoperatively with iron + EPO + transfusion.

CHEMOTHERAPY-INDUCED PULMONARY TOXICITY — BLEOMYCIN classic; risk of pulmonary fibrosis + perioperative ARDS triggered by high FiO2 (target FiO2 <40% if recent exposure, lifelong caution).

Methotrexate, busulfan, cyclophosphamide also pneumotoxic.

Get a baseline PFT/diffusion in heavily-treated patients.

Tumor-specific considerations

MEDIASTINAL MASSanterior masses (lymphoma, thymoma, germ cell) can collapse airway and cardiac structures on induction; obtain CT, evaluate flow-volume loop in upright vs supine, consider awake fiberoptic intubation, maintain spontaneous ventilation, have rigid bronchoscope/ECMO standby.

CARCINOID TUMOR — serotonin/histamine/kinin release carcinoid crisis (bronchospasm, flushing, hypotension)

octreotide 100–500 mcg pre-induction + infusion

avoid histamine-releasing drugs (morphine, atracurium, succinylcholine)

PHEOCHROMOCYTOMA — alpha-blockade 7–14 days preop, then beta-blockade

intraoperative HTN crisis managed with phentolamine/nitroprusside/nicardipine

profound hypotension after tumor venous occlusion

TUMOR LYSIS SYNDROMEaggressive treatment of bulky chemo-sensitive tumors hyperK, hyperphosphatemia, hyperuricemia, hypoCa, AKI.

Aseptic + transfusion + pain considerations

KeyStrict aseptic technique on every line; use chlorhexidine for skin prep, full barrier for central lines.

Consider FILTERED OR IRRADIATED blood for immunosuppressed (prevents transfusion-associated GVHD in stem-cell transplant, severe CMV negative patients).

PAIN — opioid-tolerant patients often (chronic cancer pain on morphine, methadone, fentanyl patch)

CONTINUE baseline opioid + add multimodal

methadone QT prolongation

ketamine helpful for opioid-refractory

regional anesthesia is generally welcome (no documented increase in cancer recurrence)

COMMUNICATIONcoordinate with oncology team on chemo schedule (don't operate at nadir), recent bleomycin exposure, recent immune checkpoint dose, pending transplant.

ETHICALcode status, goals of care, palliative vs curative intent matter for the anesthesia plan.

End of lecture

You just covered ~2 minutes of Special Populations XI. Reinforce with a few questions while it's fresh.

Practice questions →Back to lectures